Canary Speech Secures US$13M in Series A Investment

Canary Speech, an AI voice biomarker health technology start-up based in Provo, UT, has secured US$13m in series A funding.

Cortes Capital (Love’s Private Equity), Sorenson Communications, SMK, and Hackensack Meridian Health led the investment round.

The proceeds raised from the funding will help the company hire more people and grow as it expects to harness growth from the new AI technologies and the increasing need for advanced tools by the healthcare industry.

Canary Speech is an Ireland-based AI voice biomarker health technology firm that uses patented vocal-based real-time analysis for the early detection of mental and neurological diseases. Its CEO is Henry O’Connell.

The device can analyze speech data in a couple of seconds and does not require enrolling increased clinical indicators or noticeable signs of disease in such neuropsychiatric conditions as anxiety, depression, and dementia.

Canary Speech is an API-first company that uses its vocal biomarker technology in several healthcare applications. These include contact centers, ambient clinical listening, remote patient monitoring/checks, and annual health checks among patients.

Real-time audio surveillance technologies, also known as ambient listening tools, help healthcare providers concentrate on their conversations with patients. Voice recognition software helps document all clinical notes naturally.